
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Supplements and Featured Publications
about 26 years ago
Overactive Bladder: Special Considerations in the Geriatric Populationabout 26 years ago
Discussionabout 26 years ago
Bibliographyabout 26 years ago
Participating Facultyabout 26 years ago
Introduction: Overactive Bladder - Defining the Diseaseabout 26 years ago
Comorbidities Associated with Overactive Bladderabout 26 years ago
Overactive Bladder Significantly Affects Overall Quality of Lifeabout 26 years ago
Economic Considerations in Overactive Bladder





